Delivery Order SPE2DB22D1106-SPE2DB25FEZE0
- Not listed
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide the drug DARZALEX 400 MG/20 ML VIAL 20ML. The $15,511.12 contract has an ultimate completion date of April 29, 2024. AmerisourceBergen Drug Corp is the prime contractor and no set-aside designation was used. The contract was awarded under a larger indefinite delivery contract (IDC) with a potential value of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,960.42 to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800mg-30,000 15ml pharmaceutical product. This firm fixed price, non-set-aside contract was awarded on August 12, 2025, with an ultimate completion date of September 3, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $89,703.15 firm fixed price delivery order to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800MG-30,000 15ML, a specialized pharmaceutical product. The contract is unclassified as a set-aside and has an ultimate completion date of September 24, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $11,960.42 firm fixed price delivery order for DARZALEX FASPRO 1,800MG-30,000 15ML, with an ultimate completion date of July 8, 2025. This competitively awarded contract, which carries no set-aside designation, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $23,920.84 delivery order to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800MG-30,000 15ML, a specialized pharmaceutical product, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract represents a single delivery order issued under AmerisourceBergen's existing...
- The Department of Defense awarded a $23,920.80 delivery order contract to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of DARZALEX FASPR 1800 1S pharmaceutical products. This firm fixed-price delivery order, with an ultimate completion date of October 8, 2025, represents a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA). The contract was competitively awarded with no set-aside designation and will be...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $123,315.90 for DARZALEX FASPRO 1,800MG-30,000 15ML pharmaceutical product on September 19, 2025, with an ultimate completion date of October 10, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award to support federal medical procurement needs. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The U.S. Department of Defense Medical Supply Chain awarded a $71,762.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DARZALEX FASPR 1800 1S on September 4, 2025, with completion targeted for September 25, 2025. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, valued at $999,999,999.00 through December 2026. The vendor,...
- The Defense Logistics Agency awarded a $107,643.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for DARZALEX FASPRO 1,800MG-30,000 15ML pharmaceutical product, with an ultimate completion date of August 22, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery location is AmerisourceBergen's...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Darzalex Faspro 1,800mg-30,000 15ml pharmaceutical product. This non-set-aside, competitively awarded delivery order carries a ceiling value of $95,683.36 under a firm fixed price contract type, with an ultimate completion date of August 29, 2025. The award was made on August 8, 2025, and the place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FEZE0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,060.79 to AmerisourceBergen Drug Corp for the supply of DARZALEX 400 mg/20 mL vials. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. The award carries no set-aside designation, indicating the contract was competed among qualified vendors in the open market. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through December 2026. The IDC enables AmerisourceBergen to supply pharmaceutical products and medical commodities to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. As a major pharmaceutical distributor, AmerisourceBergen has established itself as a critical federal vendor through its comprehensive portfolio of brand-name and generic medications, vaccines, and medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 7/22/25 |